Article citationsMore>>
Sandhu, S.K., Schelman, W.R., Wilding, G., Moreno, V., Baird, R.D., Miranda, S., et al. (2013) The Poly(ADP-Ribose) Polymerase Inhibitor Niraparib (MK4827) in BRCA Mutation Carriers and Patients with Sporadic Cancer: A Phase 1 Dose-Escalation Trial. The Lancet Oncology, 14, 882-892.
http://dx.doi.org/10.1016/S1470-2045(13)70240-7
has been cited by the following article:
-
TITLE:
Current Possible Drug Therapies for Ovarian Cancer
AUTHORS:
Jungyeob Seoung, Young-Han Park, Chaechun Rhim, Sungju Kim
KEYWORDS:
Ovarian Cancer, Intraperitoneal Chemotherapy, Targeting Therapy
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.5 No.13,
November
7,
2014
ABSTRACT:
Ovarian cancer is the most aggressive
gynecologic cancer of the heterogenous phenotypes. Development of the new
chemotherapeutic agents and drug delivery mode makes better outcomes for
patient treatments. Optimal cytoreductive therapy followed by molecular
targeting therapy, intraperitoneal chemotherapy and dose dense chemotherapy is
a hot therapeutic concept in ovarian cancers. In our review, we will introduce
recent therapeutic advances in epithelial ovarian cancer patients.
Related Articles:
-
Randi J. Cohen, Navesh K. Sharma, Jian Q. (Michael) Yu, Lu Wang, Mark K. Buyyounouski, Michael Unger, Hossein Borghaei, Earl King, Walter Scott, Elaine Callahan, Benjamin J. Movsas, Steven J. Feigenberg
-
Daniel Oruzio, Günter Waxenecker, Christoph Aulmann, Bruno Märkl, Theodor Wagner, Geert Mudde, Manfred Schuster, Norbert Eller, Andrea Mayer, Stefan Stranner, Gottfried Himmler, Hans Loibner, Günter Schlimok, Ralf Kircheis, Andreas Nechansky
-
Roberto Kurzeja, Gerd Böhmer, Achim Schneider
-
Léon Kabamba Ngombe, Nlandu Roger Ngatu, Nyembo Mukena Christophe, Benjamin Kabyla Ilunga, Stanis Wembonyama Okitotsho, Jean-Baptiste Kakoma Sakatolo, Oscar Luboya Numbi, Brigitta Danuser
-
Masanori Hotchi, Hiroshi Okitsu, Murato Miura, Madoka Hamada, Yasuhide Sonaka, Yoh Fukuda, Tsutomu Ando, Shinji Kuratate